

**Supplemental Table 2. Statistically significant *In vitro* phenotypes of fitness gene mutants.**

Mutant	<i>E. coli</i> CFT073	<i>K.</i> <i>pneumoniae</i> KPPR1	<i>C.</i> <i>freundii</i> UMH14	<i>S.</i> <i>marcescens</i> UMH9	<i>E.</i> <i>hormaechei</i> UM_CRE_14
<i>apaGH</i>					
<i>arcA</i>	SC <sup>a</sup>	SC	SC	SC	SC
<i>arnBCADTEF</i>	PB	PB, LPS-M	PB	PB, LPS-M	- <sup>b</sup>
<i>aroC</i>	LowSid	LowSid	LowSid	LowSid	
<i>atpIBEFHAGDC</i>					
<i>gmhB</i>	BS				
<i>hscBA</i>					
<i>lpdA</i>					
<i>pdxA</i>					
<i>prc</i>	SS	SS	SS, OS	SS, OS	SS
<i>proP</i>					
<i>pstSCABphoU</i>	AP	AP	AP	AP	
<i>ruvA</i>	BS, CS	BS, CS	CS	CS	CS
<i>sapABCD</i>					
<i>tatC</i>		BS	BS	PL	
<i>ubiH</i>					
<i>wzxE</i>	SS, PB, OS, BS	SS, OS	PB, BS	SS, PB, OS, BS	SS, PB, OS
<i>xerC</i>	CS	CS	CS	CS	

<sup>a</sup>**Abbreviations:**

**SS**, human serum sensitivity; **PB**, polymyxin B sensitivity; **OS**, osmotic stress sensitivity; **BS**, bile salt sensitivity; **AP**, alkaline phosphatase overexpression; **LowSid**, mutation reduced siderophore activity; **SC**, small colony morphology; **CS**, ciprofloxacin susceptibility; **PL**, Tat-mediated protein localization; **LPS-M**, LPS modification.

<sup>b</sup>*arn* genes not present in *E. hormaechei* UMCRE14.